Kate Bingham

Overview

Kate Bingham is a Managing Partner at SV Health Investors, a venture capital firm specializing in biotechnology investments. She co-leads the firm's biotech franchise, focusing on building high-value companies that develop transformative medicines. Her investments span various drug discovery and development companies across the UK, EU, and US. SV Health Investors employs a company creation approach to biotech investing, with many portfolio companies being developed in-house. The firm invests in novel science seeking breakthroughs that address critical unmet medical needs, aiming to change therapeutic paradigms while generating attractive returns. Their expertise spans biotechnology, healthcare growth, and medtech sectors. Over the firm's 30-year history, SV Health Investors has launched 30 novel drugs, including six first-in-class therapeutics. Many of these investments were led by Kate. In 2021, she was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of experts to find and manufacture COVID-19 vaccines. Outside of SV Health Investors, Kate serves on the Board of the Francis Crick Institute and ARIA. She holds a first-class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School, where she was a Baker Scholar. SV Health Investors is a global private equity and venture capital investment platform with over $4.0 billion in historical commitments. The firm has a significant presence in the UK life sciences ecosystem with an office in London, where Kate is based, and also has an office in Boston, deeply embedding the firm in two key biotech hubs. Recent exits include EyeBio, sold to Merck & Co for up to $3 billion, and Nimbus, sold to Takeda for up to $6 billion. These exits highlight the firm's successful track record in building and exiting high-value biotech companies. SV Health Investors is committed to investing in talented innovators and strongly adheres to the view that diversity, including under-represented groups, strongly adds to success. The firm is a proud signatory of the Investing in Women Code, reflecting its commitment to diversity and inclusion in the investment process.

Investment Focus

• Innovative biotechnology companies addressing unmet medical needs
• Companies with potential to develop transformative medicines
• Startups in seed to growth stages

Portfolio Companies